What drove Vertex's revenue growth in 2025?

Growth was driven primarily by continued strong demand for CF therapies, including the newer ALYFTREK, higher realized net prices in CF in the U.S., and early contributions from CASGEVY and JOURNAVX. Full year CF-related product revenue was dominated by TRIKAFTA/KAFTRIO at $10.3 billion, with ALYFTREK contributing $838 million.

Why did GAAP net income swing so sharply from 2024 to 2025?

The 2024 GAAP net loss of $536 million was driven by $4.4 billion of acquired in-process R&D tied to the Alpine Immune Sciences acquisition. In 2025 there was no comparable charge, so GAAP net income rose to $3.95 billion, although 2025 did include a $379 million intangible asset impairment charge.

What should investors expect from Vertex in 2026?

Vertex guided to 2026 total revenue of $12.95 billion to $13.1 billion, with non-CF products contributing $500 million or more. Non-GAAP R&D, AIPR&D and SG&A expenses are expected to be $5.65 billion to $5.75 billion, and the non-GAAP effective tax rate 19.5% to 20.5%. Guidance includes approximately $100 million of AIPR&D expense and an immaterial tariff impact.

Are there any near-term pipeline catalysts?

Yes. Vertex expects to release interim data and complete the BLA submission for povetacicept in IgA nephropathy in the first half of 2026, using a priority review voucher that could shorten review from ten to six months. It also plans to submit ALYFTREK for children aged 2 to 5 and begin global submissions for CASGEVY in children aged 5 to 11 in the first half of 2026. Data from the inaxaplin interim analysis are expected in late 2026 or early 2027.

Did one-time items affect the quarter's profitability?

Yes. Q4 2025 tax expense was reduced by a one-time benefit from previously deferred tax credits and a change in prior-year liability estimates, lowering the GAAP effective tax rate to 10.5% from 19.7% a year earlier. Investors should consider these items when evaluating underlying earnings power, as the non-GAAP tax rate of 13.5% is still below the level management guides to for 2026.

VRTX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 12, 2026. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals reported strong fourth quarter and full year 2025 results, with full year total revenue of $12.0 billion^a, up 9% year over year, and fourth quarter revenue of $3.19 billion, up 10%.

Growth was driven by cystic fibrosis (CF) franchise performance, including the newer ALYFTREK, along with early contributions from CASGEVY and JOURNAVX. GAAP net income for 2025 was $3.95 billion^b (GAAP diluted EPS $15.32) versus a GAAP net loss of $536 million in 2024, a swing largely attributable to $4.4 billion of acquired IPR&D from the 2024 Alpine Immune Sciences acquisition. Non-GAAP net income was $4.75 billion.

Cash, cash equivalents and marketable securities ended the year at $12.3 billion^c. For 2026, Vertex guided to total revenue of $12.95 billion to $13.1 billion, including $500 million or more from non-CF products. Combined non-GAAP R&D, AIPR&D and SG&A expenses are expected at $5.65 billion to $5.75 billion, and the non-GAAP effective tax rate at 19.5% to 20.5%.

Management highlighted several near-term catalysts, including the planned completion of the povetacicept BLA for IgA nephropathy in the first half of 2026 (with a priority review voucher potentially shortening review to six months) and multiple pediatric regulatory submissions. The quarter also included items that flatter the reported results and merit attention.

The fourth quarter GAAP tax rate of 10.5% reflected a one-time benefit from previously deferred tax credits, and the full year 2025 results included a $379 million^d intangible asset impairment charge. Investors should weigh the strong top-line momentum against the pipeline's dependence on pending data readouts and regulatory decisions, as well as the dependence of the business on CF products, which still make up the large majority of revenue.

02—Key points

Key Highlights

Full year 2025 total revenue rose 9% to $12.0 billion; Q4 2025 total revenue rose 10% to $3.19 billion, driven by CF therapies and early launches.
U.S. revenue grew 13% for the full year to $7.55 billion, while ex-U.S. revenue grew 3% to $4.45 billion.
2026 total revenue guidance of $12.95 billion to $13.1 billion, including $500 million or more from non-CF products such as CASGEVY and JOURNAVX.
GAAP net income of $3.95 billion (diluted EPS $15.32) for 2025 versus a GAAP net loss of $536 million in 2024, which included $4.4 billion of Alpine-related AIPR&D; non-GAAP net income was $4.75 billion.
Q4 2025 tax rates were flattered by a one-time benefit from previously deferred tax credits: GAAP effective tax rate of 10.5% versus a 13.5% non-GAAP rate.
Full year 2025 included a $379 million intangible asset impairment charge, and 2026 GAAP expense guidance of $6.3 billion to $6.45 billion includes $650 million to $700 million of stock-based compensation.
Cash, cash equivalents and marketable securities increased to $12.3 billion at year-end 2025 from $11.2 billion, supported by operating cash flow net of share repurchases.

03—Questions

Frequently Asked Questions

What drove Vertex's revenue growth in 2025?
Growth was driven primarily by continued strong demand for CF therapies, including the newer ALYFTREK, higher realized net prices in CF in the U.S., and early contributions from CASGEVY and JOURNAVX. Full year CF-related product revenue was dominated by TRIKAFTA/KAFTRIO at $10.3 billion, with ALYFTREK contributing $838 million.
Why did GAAP net income swing so sharply from 2024 to 2025?
The 2024 GAAP net loss of $536 million was driven by $4.4 billion of acquired in-process R&D tied to the Alpine Immune Sciences acquisition. In 2025 there was no comparable charge, so GAAP net income rose to $3.95 billion, although 2025 did include a $379 million intangible asset impairment charge.
What should investors expect from Vertex in 2026?
Vertex guided to 2026 total revenue of $12.95 billion to $13.1 billion, with non-CF products contributing $500 million or more. Non-GAAP R&D, AIPR&D and SG&A expenses are expected to be $5.65 billion to $5.75 billion, and the non-GAAP effective tax rate 19.5% to 20.5%. Guidance includes approximately $100 million of AIPR&D expense and an immaterial tariff impact.
Are there any near-term pipeline catalysts?
Yes. Vertex expects to release interim data and complete the BLA submission for povetacicept in IgA nephropathy in the first half of 2026, using a priority review voucher that could shorten review from ten to six months. It also plans to submit ALYFTREK for children aged 2 to 5 and begin global submissions for CASGEVY in children aged 5 to 11 in the first half of 2026. Data from the inaxaplin interim analysis are expected in late 2026 or early 2027.
Did one-time items affect the quarter's profitability?
Yes. Q4 2025 tax expense was reduced by a one-time benefit from previously deferred tax credits and a change in prior-year liability estimates, lowering the GAAP effective tax rate to 10.5% from 19.7% a year earlier. Investors should consider these items when evaluating underlying earnings power, as the non-GAAP tax rate of 13.5% is still below the level management guides to for 2026.

04—Continue

← View all 8-K filings